WA
GSK icon

WealthTrust Axiom’s GSK GSK Stock Holding History

WealthTrust Axiom’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.61M Sell
68,882
-557
-0.8% -$29.5K 0.81% 32
2026
Q1 		$3.83M Sell
69,439
-157
-0.2% -$8.51K 0.94% 28
2025
Q4 		$3.41M Buy
69,596
+104
+0.1% +$4.85K 0.88% 29
2025
Q3 		$3M Sell
69,492
-3,282
-5% -$128K 0.8% 30
2025
Q2 		$2.79M Sell
72,774
-670
-0.9% -$25.6K 0.82% 31
2025
Q1 		$2.85M Buy
73,444
+5,164
+8% +$189K 0.87% 30
2024
Q4 		$2.31M Buy
68,280
+5,586
+9% +$201K 0.69% 34
2024
Q3 		$2.56M Sell
62,694
-62
-0.1% -$2.54K 0.76% 31
2024
Q2 		$2.42M Sell
62,756
-396
-0.6% -$16.7K 0.8% 30
2024
Q1 		$2.71M Buy
63,152
+2,732
+5% +$113K 0.87% 28
2023
Q4 		$2.24M Buy
60,420
+5,568
+10% +$200K 0.75% 33
2023
Q3 		$1.99M Sell
54,852
-3,275
-6% -$116K 0.72% 33
2023
Q2 		$2.07M Buy
58,127
+5
+0% +$179 0.69% 35
2023
Q1 		$2.07M Buy
58,122
+11,131
+24% +$389K 0.71% 34
2022
Q4 		$1.65M Buy
46,991
+4,593
+11% +$153K 0.58% 40
2022
Q3 		$1.25M Buy
42,398
+241
+0.6% +$9.13K 0.48% 50
2022
Q2 		$2.29M Sell
42,157
-91
-0.2% -$5.02K 0.82% 33
2022
Q1 		$2.3M Sell
42,248
-69
-0.2% -$3.75K 0.72% 38
2021
Q4 		$2.33M Sell
42,317
-3,645
-8% -$190K 0.75% 37
2021
Q3 		$2.19M Sell
45,962
-1,055
-2% -$53K 0.74% 36
2021
Q2 		$2.34M Buy
47,017
+2,650
+6% +$127K 0.75% 38
2021
Q1 		$1.98M Sell
44,367
-185
-0.4% -$8.4K 0.67% 42
2020
Q4 		$2.05M Buy
44,552
+11,330
+34% +$520K 0.74% 36
2020
Q3 		$1.56M Buy
33,222
+12,124
+57% +$607K 0.67% 39
2020
Q2 		$1.07M Sell
21,098
-954
-4% -$48.9K 0.47% 51
2020
Q1 		$1.04M Buy
22,052
+268
+1% +$14.3K 0.51% 52
2019
Q4 		$1.28M Buy
21,784
+7,442
+52% +$414K 0.43% 60
2019
Q3 		$765K Buy
14,342
+3,980
+38% +$205K 0.27% 89
2019
Q2 		$518K Sell
10,362
-637
-6% -$32K 0.18% 111
2019
Q1 		$574K Hold
10,999
– – 0.2% 103
2018
Q4 		$525K Hold
10,999
– – 0.21% 103
2018
Q3 		$552K Buy
10,999
+2,480
+29% +$126K 0.19% 110
2018
Q2 		$429K Buy
8,519
+80
+0.9% +$4.03K 0.15% 124
2018
Q1 		$412K Sell
8,439
-1,858
-18% -$86.5K 0.15% 126
2017
Q4 		$456K Buy
10,297
+342
+3% +$15.8K 0.17% 115
2017
Q3 		$505K Hold
9,955
– – 0.19% 111
2017
Q2 		$536K Buy
9,955
+202
+2% +$10.8K 0.2% 106
2017
Q1 		$513K Buy
9,753
+1,163
+14% +$59K 0.19% 113
2016
Q4 		$413K Buy
8,590
+2
+0% +$99 0.15% 129
2016
Q3 		$463K Buy
8,588
+2
+0% +$110 0.17% 115
2016
Q2 		$465K Buy
8,586
+5
+0.1% +$263 0.18% 106
2016
Q1 		$434K Sell
8,581
-521
-6% -$25.9K 0.17% 109
2015
Q4 		$459K Buy
9,102
+203
+2% +$10.3K 0.18% 106
2015
Q3 		$427K Buy
8,899
+2
+0% +$104 0.18% 103
2015
Q2 		$463K Sell
8,897
-1,633
-16% -$91.9K 0.17% 108
2015
Q1 		$607K Buy
10,530
+440
+4% +$25.2K 0.22% 96
2014
Q4 		$539K Buy
10,090
+1,002
+11% +$56.1K 0.19% 103
2014
Q3 		$522K Buy
9,088
+2
+0% +$123 0.18% 103
2014
Q2 		$607K Sell
9,086
-78
-0.9% -$5.28K 0.21% 94
2014
Q1 		$612K Buy
9,164
+244
+3% +$16.5K 0.22% 89
2013
Q4 		$595K Buy
8,920
+258
+3% +$16.7K 0.23% 86
2013
Q3 		$543K Hold
8,662
– – 0.22% 87
2013
Q2 		$541K Buy
+8,662
New +$550K 0.23% 87

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

WealthTrust Axiom's GSK Position: Q2 2026 in Review

WealthTrust Axiom reduced its GSK (GSK) stake by 0.8% in Q2 2026, selling an estimated $29.5K and leaving 68,882 shares worth $3.61M. The position accounts for 0.81% of the portfolio, ranked #32.

WealthTrust Axiom first reported a position in GSK in Q2 2013 and has held it in 53 quarters since. The position peaked at $3.83M in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • WealthTrust Axiom held 68,882 shares of GSK worth $3.61M as of Q2 2026.
  • WealthTrust Axiom sold 557 GSK shares in Q2 2026, an estimated $29.5K.
  • GSK made up 0.81% of WealthTrust Axiom's portfolio in Q2 2026, its #32 holding.
  • WealthTrust Axiom first reported a position in GSK in Q2 2013 and has held it in 53 quarters since.
  • WealthTrust Axiom's GSK position peaked at $3.83M in Q1 2026.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on WealthTrust Axiom's 13F filing for Q2 2026, filed 11 Aug 2026.